Lung Function in Patients With Early Type 2 Diabetes Mellitus

Liaoning University of Traditional Chinese Medicine200 enrolled

Overview

To investigate the protective effect of calcium dobesilate, Xuefuzhuyu Decoction, calcium dobesilate combined with Xuefuzhuyu Decoction on the early lung function of type 2 diabetes mellitus

Test group and treatment: the patients with type 2 diabetes mellitus were randomly divided into calcium dobesilate group, Xuefuzhuyu Decoction group and combination group. All participants were given hypoglycemic, metformin (1000 mg, bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO): treatment. Calcium dobesilate group were given hypoglycemic, metformin (500 mg tid, PO), to improve the circular Calcium Dobesilate Capsules (0.5 g bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO): treatment. Xuefuzhuyu Decoction group was given hypoglycemic, metformin (500 mg tid, PO), to improve the circular Xuefuzhuyu Decoction (100 ml bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO): treatment. The combined treatment group was given metformin hypoglycemic (500 mg tid, PO), Calcium Dobesilate Capsules, improve circulation (0.5 g bid, PO) + Xuefuzhuyu Decoction (100 ml, bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO). Before treatment, three groups of patients with blood glucose, oxidation related indicators, retrobulbar hemodynamics and pulmonary function were recorded. Detection: continuous treatment were observed before and after treatment of the three groups of patients after 24 weeks of fasting blood glucose (FBG), 2 hour postprandial blood glucose (2hPBG), body mass index (BMI), peripheral blood glycated hemoglobin (HbA1c) and related indexes of oxidation, superoxide dismutase (SOD), glutathione peroxidase, Gu Guang (GSH-Px), reactive oxygen species (ROS) activity, malondialdehyde (MDA) concentration and pulmonary function, vital capacity (VC%), forced vital capacity (FVC%), one second forced expiratory flow (FEV1%), peak expiratory flow (PEF%), maximal voluntary ventilation (MVV%), total lung capacity (TCL%) and a second rate (FEV1/FVC%), diffusion capacity of the lung for carbon monoxide (DLCO%), lung volume diffusion capacity of carbon monoxide (DLCO/VA%) changes of the central retinal artery (CRA) and posterior ciliary artery (PCA), eye movement The changes of blood flow velocity and resistance index (RI) of the pulse (AO) systolic and diastolic blood flow were recorded.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

200

Conditions

Type 2 Diabetes Mellitus Pulmonary Function

Interventions

Calcium DobesilateDRUG

gave each patient 0.5 g bid，

Xuefuzhuyu DecoctionDRUG

gave each patient100 ml bid，po

Xuefuzhuyu Decoction & Calcium dobesilateDRUG

gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. patients who were diagnosed with type 2 diabetes mellitus according to the guidelines of the American Diabetes Association ; 2. had no history of smoking, pulmonary disease, cold, or pulmonary infection within a two-week period; 3. were not diagnosed with hepatopathy, nephropathy, hyperuricemia, or gastrointestinal disease; 4. were likely to have good compliance and were able to visit our hospital for periodic assessments. Exclusion Criteria: 1. , type 1 diabetes, pregnant women; 2. there are important organ dysfunction; 3. the need to control blood glucose after insulin injection (poor drug control); 4. the life of patients with irregular or serious addiction (alcoholism), 5. poor compliance and compliance; 6. the experiment of drug intolerance (severe allergic reaction 6); 7. hypertension and hyperuricemia; 8. and nearly two weeks colds, pneumonia and other respiratory diseases.

Outcomes

Primary Outcomes

Changes in pulmonary function parameters

The primary endpoints were the between-group differences in the changes in pulmonary function parameters between pretherapy and posttreatment

Time frame: 26 weeks

Secondary Outcomes

Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,

The secondary endpoints were changes from baseline to week 26 in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,. The tertiary endpoints were the changes from baseline to week 26 in blood-fat

Time frame: 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.